As of Jul 02
| -0.23 / -1.90%|
The 5 analysts offering 12-month price forecasts for Nektar Therapeutics have a median target of 17.00, with a high estimate of 19.00 and a low estimate of 13.00. The median estimate represents a +42.98% increase from the last price of 11.89.
The current consensus among 6 polled investment analysts is to Buy stock in Nektar Therapeutics. This rating has held steady since June, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.